Products for Research Use Only
RegisterLogin

Thioridazine

CAT: 0804-HY-B0965A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0965A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs) [1][2][3][4].
CAS Number
50-52-2
UNSPSC
12352005
Hazard Statement
H302
Target
5-HT Receptor; Apoptosis; Autophagy; Bacterial; Dopamine Receptor
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/thioridazine.html
Purity
99.50
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CSC(C=C1N2CCC3N(C)CCCC3)=CC=C1SC4=C2C=CC=C4
Molecular Formula
C21H26N2S2
Molecular Weight
370.57
Precautions
H302
References & Citations
[1]Tschanz JT, et, al. Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1988 Nov;31 (3) :519-22.|[2]Mu J, et, al. Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer. Oncol Rep. 2014 May;31 (5) :2107-14.|[3]Kang S, et, al. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells. Apoptosis. 2012 Sep;17 (9) :989-97.|[4]Loehr AR, et, al. Targeting Cancer Stem Cells with Differentiation Agents as an Alternative to Genotoxic Chemotherapy for the Treatment of Malignant Testicular Germ Cell Tumors. Cancers (Basel) . 2021 Apr 23;13 (9) :2045.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Int J Mol Sci. 2023 Jan 13;24 (2) :1635.|bioRxiv. 2025 Nov 21:2025.11.20.689520.|Br J Cancer. 2024 Oct;131 (7) :1212-1223.|Int J Biol Macromol. 2022 Feb 15:198:1-10.|Pol J Microbiol. 2019 Dec;68 (4) :477-491.

Alternative Products

CatalogName
E7923-5mgThioridazine
MBS385729-01Thioridazine hydrochloride
TRC-T539260-50MGThioridazine Disulfoxide
A8537-1000Thioridazine HCl

Popular Products